Amgen Posts Strong Phase 3 Trial Data for Subcutaneous Tepezza
By Adriano Marchese
Amgen reported positive results from its phase 3 trials of its thyroid eye disease treatment.
The biotechnology company said Monday that its under-the-skin version of Tepezza met its primary endpoints in treating moderate-to-severe thyroid eye disease, showing a 77% proptosis response rate, where there is a forward bulging of the eye, during the 24-week placebo-controlled period.
Thyroid eye disease is a rare autoimmune condition in which the body's immune system mistakenly attacks the tissues around the eyes.
Amgen said the effects of the subcutaneous version of the drug showed comparable results to the intravenous form of the medication.
Additionally, the company said the subcutaneous trial also showed strong improvements across many secondary measures of the disease, such as improvement for patients with double vision, called diplopia.
On the safety performance front, the company said the overall results were similar to its IV version.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
April 06, 2026 09:48 ET (13:48 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
United States